100% Same
Salt CompositionEffectivenessStrength
with Substitute Medicine
Venlafaxine 37.5mg


WHO GMP
Certified

15 Days Easy
Returns

Long Expiry
(>8 Months)

WHO GMP
Certified

15 Days Easy
Returns

Long Expiry
(>8 Months)
Delivery by
In Depression : Venozap 37.50 ER Tablet helps in maintaining the balance of certain chemicals in the brain that affect mood and behavior. This improves your mood, relieves anxiety, tension, helps you sleep better, and increases your energy levels. Venozap 37.50 ER Tablet prevents extreme mood changes and helps you feel less agitated. You may experience fewer episodes of depression and low mood.In Anxiety disorder Venozap 37.50 ER Tablet works by stopping your brain from releasing the chemicals that make you feel anxious so it can reduce the symptoms of excessive anxiety and worry. It can also reduce feelings of restlessness, tiredness, difficulty concentrating, irritability, and sleep problems that often come with Anxiety disorder. It will therefore help you go about your daily activities more easily and be more productive. Keep taking this medicine even if you feel well. Stopping suddenly can cause serious problems.show moreshow less
Side effects of Venozap Tablet ERThe majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you�re worried about them Common side effects of Venozap Nausea Vomiting Dizziness Insomnia (difficulty in sleeping)Decreased appetite Anxiety Constipation Increased sweating Sexual dysfunction
How to use Venozap Tablet ERFollow your doctor's guidance regarding the dose and duration of this medication. Ingest it without breaking or crushing. Do not chew, crush or break it. Venozap 37.50 ER Tablet is to be taken with food.
How Venozap Tablet ER works Venozap 37.50 ER Tablet works by increasing the levels of chemical messengers (serotonin and noradrenaline), natural substances in the brain that help maintain mental balance.
Unsafe: Avoid consuming alcohol with Venozap 37.50 ER Tablet as it is deemed unsafe.
Venozap 37.50 ER Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Doctor consultation is advised.
Venozap 37.50 ER Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.Babies should be monitored for excessive sleepiness and adequate weight gain.
Venozap 37.50 ER Tablet may cause side effects which could affect your ability to drive.As side effects of Venozap 37.50 ER Tablet are dizziness, confusion and eye sight changes such as blurred vision and this may affect your ability to drive.
Venozap 37.50 ER Tablet should be used with caution in patients with kidney disease. Dose adjustment of Venozap 37.50 ER Tablet may be needed. Doctor consultation is advised.
Venozap 37.50 ER Tablet should be used with caution in patients with liver disease. Dose adjustment of Venozap 37.50 ER Tablet may be needed. Doctor consultation is advised.
If a dose of Venozap 37.50 ER Tablet is missed, take it promptly. However, if your next dose is approaching, skip the missed dose and resume your regular schedule. Avoid doubling the dose.
#4025/26, K.R. Road,Jayanagar 7th Block,Bangalore,Karnataka ‚ 560027,India
Stahl SM, editor. Venlafaxine. In: Stahl's Essential Pschopharmacology: Prescriber's Guide. 5th ed. New York, New York: Cambridge University Press; 2014. pp. 721-26
DeBattista C. Antidepressant Agents. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. p. 513
Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. p. 1466
Venlafaxine (19 Mar. 2019)
Drugs and Lactation Database (LactMed) (20 Feb. 2020)
Central Drugs Standard Control Organisation (CDSCO) (19 Mar. 2019)
Venlafaxine hydrochloride (18 Feb. 2025)
Venlafaxine Extended-Release (18 Feb. 2025)
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.